NCT06378047View on ClinicalTrials.gov

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Pancreatic CancerLocally Advanced Pancreatic Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab is an immunotherapy that will be administered via IV infusion.

DEVICE

Irreversible Electroporation

Participants will undergo IRE as standard of care treatment.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Angiodynamics, Inc.
All Listed Sponsors
collaborator

Angiodynamics, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER